Status: Not yet recruiting
(TNX-1500) in Kidney Transplant Recipients
The primary objective is to investigate the safety and efficacy of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.
Participants needed: 5
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Ayman Al Jurdi, MDUpdated: Feb 25, 2026Locations: 2
Eligibility criteria
Male or female subjects ≥18 to 75 years of age. [+4]
Recipient seropositive for human immunodeficiency virus (HIV-1), or hepatitis B... [+22]